Hydrus Microstent

Growing number of devices set to transform glaucoma treatmentMinimally invasive glaucoma surgery (MIGS) is the latest development in the treatment of glaucoma. With two MIGS devices already approved in the United States, there are a variety of novel devices that have the potential to transform the treatment of glaucoma.
Evolution in glaucoma surgery mounting with MIGS proceduresAn expanding armamentarium of minimally invasive and micro-invasive glaucoma surgery procedures is transforming glaucoma management.
Microstent demonstrates stable treatment benefit compared with cataract surgery aloneEyes undergoing implantation with an investigational Schlemm’s canal microstent at the time of cataract surgery achieve significantly greater IOP control than eyes having cataract surgery alone.
New glaucoma devices bring new dimension of treatment
Innovation in glaucoma thrivingThe glaucoma pharmaceutical sector alone is set to grow from $4 billion in 2013 to $5 billion by 2018. Innovation in glaucoma diagnosis and treatment is alive, well–and profitable. That was the upbeat report from Emmett Cunningham, Jr., MD, PhD, MPH, ophthalmologist and partner with venture capital firm Clarus Ventures, LLC.